Dawood Shaheenah, Sirohi Bhawna
Department of Medical Oncology, Dubai Hospital, United Arab Emirates.
Future Oncol. 2015;11(6):923-31. doi: 10.2217/fon.15.7.
Pertuzumab is a humanized monoclonal antibody targeting HER2 that is different from trastuzumab in that it binds to a different domain of HER2; hence, combining the two drugs leads to a more comprehensive blockade of the receptor. This is the first drug to receive fast-track approval from US FDA based on the pathologic complete response (as the primary end point) attained in patients treated with neoadjuvant chemotherapy for breast cancer. Pertuzumab is approved in first-line treatment in metastatic setting both by FDA and EMA in combination with trastuzumab and docetaxel. Combining two targeted therapies ('dual blockade') will certainly escalate treatment costs and it remains to be seen if this strategy will find its way in to the clinic for all patients.
帕妥珠单抗是一种靶向HER2的人源化单克隆抗体，它与曲妥珠单抗不同，因为它结合HER2的不同结构域；因此，将这两种药物联合使用可更全面地阻断该受体。这是第一种基于乳腺癌新辅助化疗患者获得的病理完全缓解（作为主要终点）而获得美国食品药品监督管理局快速通道批准的药物。帕妥珠单抗已获美国食品药品监督管理局和欧洲药品管理局批准，与曲妥珠单抗和多西他赛联合用于转移性乳腺癌的一线治疗。联合两种靶向治疗（“双重阻断”）肯定会提高治疗成本，这种策略是否会应用于所有患者的临床治疗还有待观察。
